SurModics, Inc. (SRDX) Responds to Merck’s Termination of License and Research Collaboration
SurModics, Inc. (NASD: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, recently announced that Merck & Co., Inc. has notified the company that it will discontinue the License and Research Collaboration Agreement the companies signed in June 2007. Shares of SurModics declined sharply earlier this week after the announcement. Merck's decision triggers an additional $9 million payment to SurModics from Merck. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Clinical data on I-vation TA generated to…